Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

Inc. will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial results ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.

Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid ...

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter net income of $1.05 billion. On a per-share basis, the Boston-based company said it had net income of $4 ...